Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer

June 26th 2024

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.

Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer

June 26th 2024

Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer.

Dr Freedland on Implications of Treatment Suspension on HRQOL in High-Risk nmHSPC

June 26th 2024

Stephen J. Freedland, MD, discusses the effects of treatment suspension on HRQOL in nonmetastatic hormone-sensitive prostate cancer in the EMBARK trial.

Dr Kyriakopoulos on Adding Cabazitaxel to Abiraterone/Prednisone in Patients With MCRPC

June 25th 2024

Christos Kyriakopoulos, MD discusses adding cabazitaxel to abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer.

ARASENS Trial Demonstrates Significant Survival Benefits With Triplet Therapy in mHSPC

June 25th 2024

Darolutamide plus ADT and docetaxel showed improved outcomes in patients with metastatic hormone-sensitive prostate cancer.

Dr Grimm on Post-Progression OS After Darolutamide Plus ADT/Docetaxel in mHSPC

June 21st 2024

Marc-Oliver Grimm, MD discusses darolutamide in combination with androgen deprivation therapy and docetaxel in mHSPC.

Dr Choudhury on the Evaluation of Treatment Interruption After Response in mHSPC

June 17th 2024

Atish D. Choudhury, MD, PhD, on a phase 2 trial evaluating ADT interruption in metastatic hormone-sensitive prostate cancer after AR inhibitor response.

Hypofractionation is Noninferior to Conventional Fractionation Radiotherapy in Low-Risk Prostate Cancer

June 12th 2024

Hypofractionation radiotherapy was noninferior to conventional fractionation radiotherapy for the treatment of patients with low-risk prostate cancer.

JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise

June 10th 2024

A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

June 10th 2024

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

June 7th 2024

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

June 6th 2024

Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.

Dr D’Amico on Genomic Classifiers in Prostate Cancer

June 5th 2024

Anthony V. D'Amico, MD, PhD, discusses the Decipher Genomic Classifier in prostate cancer treatment.

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC

June 5th 2024

Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.

Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC

June 1st 2024

Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.

Dr Yap on the Continued Investigation of Saruparib in Advanced Solid Tumors

May 30th 2024

Timothy Yap, MBBS, PhD, FRCP, discusses next steps for investigating saruparib in advanced solid tumors with genetic mutations, including prostate cancer.

PSMA Response Is Associated With MFS Improvement in Oligometastatic CSPC

May 30th 2024

PSMA response was associated with improved metastasis-free survival in oligometastatic castration-sensitive prostate cancer.

Dr Yap on the Investigation of Saruparib in Solid Tumors

May 28th 2024

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.

Broadening Differentials in Brain-Metastatic Prostate Cancer Expand Diagnostic Horizons

May 28th 2024

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer

May 28th 2024

The FDA has received a new drug application for the use of TLX007-CDx in the preparation of PSMA PET imaging of prostate cancer.